1. Home
  2. AZTA vs MESO Comparison

AZTA vs MESO Comparison

Compare AZTA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AZTA
  • MESO
  • Stock Information
  • Founded
  • AZTA 1978
  • MESO 2004
  • Country
  • AZTA United States
  • MESO Australia
  • Employees
  • AZTA N/A
  • MESO N/A
  • Industry
  • AZTA Industrial Machinery/Components
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AZTA Technology
  • MESO Health Care
  • Exchange
  • AZTA Nasdaq
  • MESO Nasdaq
  • Market Cap
  • AZTA 1.4B
  • MESO 1.3B
  • IPO Year
  • AZTA 1995
  • MESO N/A
  • Fundamental
  • Price
  • AZTA $30.92
  • MESO $17.07
  • Analyst Decision
  • AZTA Buy
  • MESO Buy
  • Analyst Count
  • AZTA 4
  • MESO 2
  • Target Price
  • AZTA $42.00
  • MESO $24.00
  • AVG Volume (30 Days)
  • AZTA 541.0K
  • MESO 259.1K
  • Earning Date
  • AZTA 11-11-2025
  • MESO 08-28-2025
  • Dividend Yield
  • AZTA N/A
  • MESO N/A
  • EPS Growth
  • AZTA N/A
  • MESO N/A
  • EPS
  • AZTA N/A
  • MESO N/A
  • Revenue
  • AZTA $668,821,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • AZTA N/A
  • MESO $288.50
  • Revenue Next Year
  • AZTA $4.01
  • MESO $167.17
  • P/E Ratio
  • AZTA N/A
  • MESO N/A
  • Revenue Growth
  • AZTA 12.46
  • MESO 191.39
  • 52 Week Low
  • AZTA $23.91
  • MESO $7.09
  • 52 Week High
  • AZTA $55.64
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • AZTA 50.65
  • MESO 50.15
  • Support Level
  • AZTA $29.52
  • MESO $17.55
  • Resistance Level
  • AZTA $32.79
  • MESO $18.50
  • Average True Range (ATR)
  • AZTA 1.37
  • MESO 0.60
  • MACD
  • AZTA 0.05
  • MESO -0.11
  • Stochastic Oscillator
  • AZTA 58.06
  • MESO 30.77

About AZTA Azenta Inc.

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: